Ezetimibe

CAS 163222-33-1

Signals from filings dated January 2026 – January 2026 · Last checked 7 Nov 2026

Supply outlook

↑ GROWING

In the filings we track: 1 plant adding this molecule, 0 exit signals, 0 intermediate projects.

↑ Coming in1 plant0 t/yr, where filed in tonnes
↓ Leaving0no drops or surrenders found
⇄ Own intermediates0no KSM projects found
Furthest stageHearingno clearance granted yet

Signals

Sy. No. 667, Bhiknoor, Kamareddy, Telangana

  1. ✓ Terms of reference
  2. ✓ Public hearing · 7 Jan 2026
  3. Next: clearance
  4. Consent to operate
  5. DMF / CEP

New product at the site, 30 kg/day. Expansion of an approved API unit still under construction (EC 2021; taken over by Fusion Health Care in 2023). Worst case 6 products run at once; site total 1,000 to 2,420 kg/day. Public hearing held 7 Jan 2026. Source: EIA executive summary, TGPCB

Why capacity is shown as filed →

Who makes Ezetimibe today: 35 listings

Current manufacturers with US DMF and CEP status, plant addresses and contacts.

See all manufacturers →
ManufacturerCountryUS DMFCEPContact
MSN Laboratories LtdIndia✓—In database
Teva Pharmaceutical Industries LtdIsrael✓—In database
CHANGZHOU PHARMACEUTICAL FACTORYChina✓—In database
+ 32 more listings in api-fdf.com →

Three examples from the api-fdf.com database, refreshed weekly. Plant addresses and contacts are shown in the database.

Follow Ezetimibe

Get an email when a new filing adds, cuts or moves this molecule to the next stage.

Follow

Other molecules with signals